ACP-204-006
Alzheimer’s Disease Psychosis
-
Open enrollment Study for Alzheimer's Disease with hallucinations or delusions
The main goal of the study is to evaluate the safety and effectiveness of a potential new drug, for treating psychosis symptoms—such as hallucinations and delusions—in people with Alzheimer’s disease dementia (ADP). Researchers aim to determine how well the study drug works, what the best dose may be, and what side effects it might cause. The hope is to provide a meaningful treatment option that could improve the lives of those affected by ADP and their care partners.
-
Participation involves:
- Screening period (about 7 weeks) – completed prior to the treatment phase
- Study treatment period (about 6 weeks) – approximately 5 study center visits; daily study medication
- Follow-up period (about 30 days) – includes safety monitoring after the treatment phase
-
We are looking for patients who are:
- Experiencing hallucinations, delusions, or unusual thoughts or feelings
- Becoming suspicious or fearful
- Feeling or believing things that are false or unreal
- Supported by a Care Partner who is in frequent contact and can assist with study visits and assessments
- This is not a complete list of requirements. The study staff will provide full details during screening.
Application for Current Clinical Research Study
Research Study
ACP-204-006 Study: Alzheimer's Disease Psychosis
Please enter your Full Legal Name
-
What else do I need to consider?
- Participation is voluntary and can be stopped at any time.
- Study drugs, clinic visits, and related tests are provided at no cost.
- Participants must follow all instructions, take the medication as directed, and attend all study visits.
- Participants should not join other studies while enrolled in this one.
- The participant’s safety will be closely monitored by medical professionals throughout the study.
